| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 1
Volume 49 Number 6
Volume 49 Number 5
Volume 49S Number 1
Volume 49 Number 4
Volume 49 Number 3
Earlier issues
Volume  Number 

previous article next article

Research articles

ScienceAsia 49 (2023):ID 403-410 |doi: 10.2306/scienceasia1513-1874.2023.029

In vitro anticancer efficacy of silibinin-loaded PLGA nanofibers against A549 non-small-cell lung cancer cells

Qiong Wu, Shiguang Xu, Wei Xu, Hao Meng*

ABSTRACT:     In recent years, amount of evidence suggests that silibinin (SLB), an active constituent isolated from the seeds of Silybum marianum, possesses pleiotropic anticancer effects in different cancers. In this study, poly (lactic-coglycolic acid) (PLGA) polymer was used to fabricate SLB containing nanofibers (NFs) by the electrospinning method. The NFs were characterized by their unique morphological features, degradation rate, and drug release profile. The cytotoxic effects, production of intracellular reactive oxygen species (ROS), and the gene expression of apoptotic proteins were investigated in A549 human lung adenocarcinoma cells and normal human lung epithelial cell line (BEAS-2B cells) treated with free SLB and SLB-loaded PLGA NFs. The results indicated that both free SLB and SLBloaded NFs had no effect on BEAS-2B cells, but were cytotoxic against A549 cells, increasing intracellular ROS levels in cancer cells. In addition, both agents induced the gene expression of apoptotic proteins, and the SLB-loaded NFs acted more efficiently than the free SLB. With further study, hence, the SLB-loaded NFs could be potentially used as an anti-cancer agent against human lung adenocarcinoma.

Download PDF

74 Downloads 478 Views

a Department of Thoracic Surgery, General Hospital of Northern Theater Command, Shenyang 110011 China

* Corresponding author, E-mail: mh7713642@sina.com

Received 26 Apr 2022, Accepted 11 Dec 2022